CompletedPhase 2

Tafenoquine in Patients With Mild to Moderate COVID-19

United States86 participantsStarted 2021-02-19

Plain-language summary

A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. G6PD deficiency
✕. Breastfeeding
✕. Psychotic disorder or current psychotic symptoms
✕. Known hypersensitivity reaction to TQ
✕. Clinical signs indicative of severe systemic illness with COVID-19, such as respiratory rate ≥30 breaths per minute, heart rate ≥ 125 beats per minute, SpO2 ≤93% on room air
✕. Respiratory failure defined based on resource utilization requiring at least one of the following:

Number of Patients With Clinical Recovery of COVID-19 Symptoms on Day 14

Timeframe: Day 14 [± 1 day]

NCT IDNCT04533347

Sponsor60 Degrees Pharmaceuticals LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-06-30

Results submitted2024-12-13